Clinical Pathology in Cancer: From Diagnosis to Precision Medicine
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 771
Editor
Interests: cancer biomarkers; immunohistochemistry; cancer pathogenesis; molecular biology of cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Traditionally, pathologists have been regarded as the gatekeepers of cancer diagnostics. In the rapidly evolving era of targeted therapy, pathology has evolved into one of the cornerstones of precision cancer medicine. The advances in molecular biology have tremendously affected the practice of pathology, transforming it from a solely morphology-based discipline into a molecular-based one. Molecular testing in pathological specimens is increasingly being incorporated into daily practice, serving not only as a tool for the accurate diagnosis, but also for the assessment of clinically relevant biomarkers with prognostic and predictive value to tailor therapeutic interventions (next generation pathology).
This Special Issue aims to focus on advanced diagnostic approaches, cancer biomarkers and molecular tests in cancer pathology. We are happy to invite pathologists and researchers to submit original research articles, comprehensive reviews and case reports to this Special Issue.
You may choose our Joint Special Issue in Cancer.
Prof. Dr. Georgia Levidou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biomarkers
- precision medicine
- histopathology
- clinical pathology
- diagnosis
- prognostic/predictive biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
